New Risk • May 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$30.5m market cap, or US$22.1m). Major Estimate Revision • Feb 25
Consensus EPS estimates fall by 26% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from AU$31.4m to AU$29.9m. Losses expected to increase from AU$0.015 per share to AU$0.019. Healthcare Services industry in Australia expected to see average net income growth of 17% next year. Consensus price target down from AU$0.60 to AU$0.30. Share price fell 9.4% to AU$0.14 over the past week. Reported Earnings • Feb 20
First half 2026 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in 1H 2025) First half 2026 results: AU$0.01 loss per share (improved from AU$0.011 loss in 1H 2025). Revenue: AU$14.5m (up 2.1% from 1H 2025). Net loss: AU$2.87m (loss narrowed 12% from 1H 2025). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. New Risk • Feb 19
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-AU$2.3m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$1.4m net loss in 2 years). Market cap is less than US$100m (AU$46.5m market cap, or US$32.8m). Ankündigung • Jan 28
Beamtree Holdings Limited to Report First Half, 2026 Results on Feb 25, 2026 Beamtree Holdings Limited announced that they will report first half, 2026 results on Feb 25, 2026 Ankündigung • Oct 02
Beamtree Holdings Limited, Annual General Meeting, Nov 27, 2025 Beamtree Holdings Limited, Annual General Meeting, Nov 27, 2025. Location: at level 5, 126 phillip street, nsw 2000, sydney Australia Recent Insider Transactions • Sep 05
Non-Executive Director recently bought AU$62k worth of stock On the 3rd of September, Brad Lancken bought around 278k shares on-market at roughly AU$0.22 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Major Estimate Revision • Sep 03
Consensus revenue estimates decrease by 12%, EPS upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from AU$35.7m to AU$31.4m. EPS estimate increased from -AU$0.016 to -AU$0.015 per share. Healthcare Services industry in Australia expected to see average net income growth of 7.1% next year. Consensus price target down from AU$0.70 to AU$0.60. Share price fell 15% to AU$0.23 over the past week. Reported Earnings • Aug 29
Full year 2025 earnings: Revenues miss analyst expectations Full year 2025 results: Revenue: AU$25.0m (down 9.4% from FY 2024). Net loss: AU$6.20m (loss widened 21% from FY 2024). Revenue missed analyst estimates by 5.9%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Australia. Ankündigung • Aug 25
Beamtree Holdings Limited to Report Fiscal Year 2025 Results on Aug 28, 2025 Beamtree Holdings Limited announced that they will report fiscal year 2025 results on Aug 28, 2025 Recent Insider Transactions Derivative • Jun 04
Non-Executive Director exercised options to buy AU$111k worth of stock. On the 2nd of June, Brad Lancken exercised options to buy 375k shares at a strike price of around AU$0.20, costing a total of AU$75k. This transaction amounted to 16% of their direct individual holding at the time of the trade. Since June 2024, Brad's direct individual holding has increased from 2.27m shares to 2.35m. This was the only transaction from an insider over the last 12 months. New Risk • Apr 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$2.3m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$53.6m market cap, or US$34.3m). Ankündigung • Mar 10
Beamtree Holdings Limited Announces Board Changes, Effective from 31 March 2025 Beamtree Holdings Limited announced the appointment of Professor Andy Hardy to the board of directors, effective 31 March 2025. Professor Hardy is Chief Executive Officer of University Hospitals Coventry and Warwickshire NHS Trust (UHCW), one of the largest tertiary acute hospital Trusts in England. He is also Deputy Chair of the National Improvement Board and on the board of a number of organisations, including the West Midlands Cancer Alliance and is a member of the Beamtree Global Impact Committee. In January 2016 Andy was appointed Professor of Industry at the University of Warwick and in 2022 awarded the Honorary Degree of Doctor of Business Administration at Coventry University in recognition of his leadership and significant contribution to healthcare provision across Coventry and Warwickshire. In April 2023 he accepted the appointment of Professor for the Vice Chancellor's Health Advisory Board, Coventry University. Andy has served as the President of Chartered Institute of Public Finance and Accountancy and the Healthcare Financial Management Association. After four years at Beamtree leading the Global Impact Committee (GIC) and being a board member from 2024, Professor Mark Britnell has decided to focus on his UK commitments now that he has become chair of Health Innovation Manchester and will be stepping down from the board and the GIC effective 31 March 2025. Major Estimate Revision • Feb 25
Consensus EPS estimates fall by 51% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from AU$33.4m to AU$30.4m. Losses expected to increase from AU$0.011 per share to AU$0.017. Healthcare Services industry in Australia expected to see average net income growth of 7.3% next year. Consensus price target of AU$0.70 unchanged from last update. Share price fell 22% to AU$0.23 over the past week. Reported Earnings • Feb 21
First half 2025 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2024) First half 2025 results: AU$0.011 loss per share (in line with 1H 2024). Revenue: AU$14.2m (up 9.9% from 1H 2024). Net loss: AU$3.25m (loss widened 12% from 1H 2024). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. New Risk • Feb 20
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: AU$5.5m Forecast net loss in 2 years: AU$2.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$2.3m net loss in 2 years). Market cap is less than US$100m (AU$75.3m market cap, or US$47.8m). Ankündigung • Jan 30
Beamtree Holdings Limited to Report First Half, 2025 Results on Feb 19, 2025 Beamtree Holdings Limited announced that they will report first half, 2025 results on Feb 19, 2025 Ankündigung • Nov 29
Beamtree Holdings Limited Announces the Resignation of Belinda Cleminson as Joint Company Secretary Beamtree Holdings Limited announced that Ms Belinda Cleminson has resigned as Joint Company Secretary, effective immediately. Ms Cleminson's resignation is a result of her resignation from Automic Group, the Company's corporate secretarial service provider. Ms Maria Clemente of Automic Group will continue in her role as sole Company Secretary and person responsible for communications with ASX in relation to Listing Rule matters under ASX Listing Rule 12.6. New Risk • Oct 20
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (AU$71.0m market cap, or US$47.6m). Ankündigung • Oct 18
Beamtree Holdings Limited, Annual General Meeting, Nov 28, 2024 Beamtree Holdings Limited, Annual General Meeting, Nov 28, 2024. Location: at level 5, 126 phillip street, sydney nsw 2000 Australia Ankündigung • Oct 15
Tim Kelsey to Step Down as CEO of Beamtree Holdings Limited in March 2025 Beamtree Holdings Limited announced that, after more than four years, Tim Kelsey will be stepping down as Beamtree CEO in early 2025. Mr. Kelsey has overseen a remarkable transformation in the Sydney-based company which is now established as a global healthcare pioneer in AI, data analytics and decision support. Mr. Kelsey will be stepping down in March 2025 in order to pursue new opportunities in international healthcare. A search will now be launched for his successor. Mr. Kelsey will become chair of Beamtree's Global Impact Committee (GIC) when he finishes as CEO, replacing Prof Mark Britnell, who has recently joined the Beamtree Board as a non-executive director and who has completed his three-year term as GIC chair. Tim is fully committed to delivering Beamtree's first half of fiscal year 2025 results and will retain a consulting role post his retirement as CEO. Reported Earnings • Aug 28
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: AU$0.018 loss per share (improved from AU$0.028 loss in FY 2023). Revenue: AU$28.1m (up 24% from FY 2023). Net loss: AU$5.11m (loss narrowed 26% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 27%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. New Risk • Aug 06
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: AU$5.7m Forecast net loss in 2 years: AU$1.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$1.8m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Market cap is less than US$100m (AU$69.4m market cap, or US$45.0m). Major Estimate Revision • Feb 20
Consensus EPS estimates upgraded to AU$0.017 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -AU$0.021 to -AU$0.017 per share. Revenue forecast unchanged from AU$27.6m at last update. Healthcare Services industry in Australia expected to see average net income growth of 38% next year. Consensus price target of AU$0.70 unchanged from last update. Share price fell 2.2% to AU$0.23 over the past week. Reported Earnings • Feb 16
First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.017 loss in 1H 2023) First half 2024 results: AU$0.011 loss per share (improved from AU$0.017 loss in 1H 2023). Revenue: AU$12.9m (up 23% from 1H 2023). Net loss: AU$2.90m (loss narrowed 30% from 1H 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance. Ankündigung • Jan 25
Beamtree Holdings Limited to Report First Half, 2024 Results on Feb 14, 2024 Beamtree Holdings Limited announced that they will report first half, 2024 results on Feb 14, 2024 Ankündigung • Oct 20
Beamtree Holdings Limited, Annual General Meeting, Nov 21, 2023 Beamtree Holdings Limited, Annual General Meeting, Nov 21, 2023, at 16:00 AUS Eastern Standard Time. Location: Level 5, 126 Phillip Street Sydney New South Wales Australia Agenda: To receive and to consider the Annual Financial Report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Directors' Report, the Remuneration Report and the Auditor's Report for that financial year; to consider adoption of Remuneration Report; to consider re-election of James Birch as Director; to consider re-election of Michael Hill as Director; to consider ratification of prior issue of 956,673 Fully Paid Ordinary Shares; to consider ratification of prior issue of 20,000,000 Fully Paid Ordinary Shares; to consider approval of Related Party Participation in the Placements; to consider approval of Issue of Rights to Stephen Borness, a Director of the Company; to consider approval of Issue of Rights to Michael Hill, a Director of the Company; to consider approval of Issue of Rights to Bradley Lancken, a Director of the Company; and to transact other matters. Reported Earnings • Aug 25
Full year 2023 earnings: Revenues miss analyst expectations Full year 2023 results: Revenue: AU$22.8m (up 38% from FY 2022). Net loss: AU$6.90m (loss widened 55% from FY 2022). Revenue missed analyst estimates by 1.2%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia. New Risk • Aug 25
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (AU$58.6m market cap, or US$37.5m). Ankündigung • Aug 24
Beamtree Holdings Limited Provides Earnings Guidance for the Full Year 2024 Beamtree Holdings Limited provided earnings guidance for the full year 2024. For the year, the company expected organic revenue growth of +20% and positive operating profit. New Risk • Aug 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (AU$1.3m net loss in 3 years). Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (AU$62.6m market cap, or US$40.3m). Ankündigung • Aug 16
Beamtree Holdings Limited to Report Fiscal Year 2023 Results on Aug 24, 2023 Beamtree Holdings Limited announced that they will report fiscal year 2023 results on Aug 24, 2023 Ankündigung • May 29
Beamtree Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 5.23 million. Beamtree Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 5.23 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: AUD 0.25
Discount Per Security: AUD 0.01
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 920,000
Price\Range: AUD 0.25
Discount Per Security: AUD 0.01
Transaction Features: Subsequent Direct Listing Buying Opportunity • Mar 06
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be AU$0.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 62% over the last 3 years. Earnings per share has declined by 97%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings is also forecast to grow by 61% per annum over the same time period. Ankündigung • Feb 01
Beamtree Holdings Limited to Report First Half, 2023 Results on Feb 15, 2023 Beamtree Holdings Limited announced that they will report first half, 2023 results on Feb 15, 2023 Major Estimate Revision • Dec 20
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 expected loss increased from -AU$0.02 to -AU$0.03 per share. Revenue forecast of AU$22.3m unchanged since last update. Healthcare Services industry in Australia expected to see average net income growth of 22% next year. Consensus price target up from AU$0.60 to AU$0.70. Share price rose 7.9% to AU$0.34 over the past week. Major Estimate Revision • Dec 06
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 losses forecast to reduce from -AU$0.02 to -AU$0.02 per share. Revenue forecast unchanged from AU$22.3m at last update. Healthcare Services industry in Australia expected to see average net income growth of 22% next year. Consensus price target of AU$0.60 unchanged from last update. Share price was steady at AU$0.32 over the past week. Ankündigung • Nov 30
Beamtree Holdings Limited Appoints Emma Gray as Director Beamtree Holdings Limited announced the appointment of Emma Gray as Director. Date of appointment is 24 November 2022. Price Target Changed • Nov 16
Price target increased to AU$0.60 Up from AU$0.33, the current price target is provided by 1 analyst. New target price is 193% above last closing price of AU$0.20. Stock is down 57% over the past year. The company is forecast to post a net loss per share of AU$0.023 next year compared to a net loss per share of AU$0.019 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Andy Gray was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 17
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Andy Gray was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Oct 05
Beamtree Holdings Limited Announces Executive Changes Beamtree Holdings Limited announced that Paul Williams and Andrew Gray will retire from the Beamtree board on the same date at the AGM. Both Paul and Andrew have significantly contributed to the Beamtree board from the date of the IPO. Both Paul and Andrew will remain as Directors up until their resignation on the 24th November 2022. Ankündigung • Aug 26
Beamtree Holdings Limited, Annual General Meeting, Oct 27, 2022 Beamtree Holdings Limited, Annual General Meeting, Oct 27, 2022. Location: 16 Eveleigh Street Redfern New South Wales Australia Reported Earnings • Aug 24
Full year 2022 earnings released: AU$0.018 loss per share (vs AU$0.002 loss in FY 2021) Full year 2022 results: AU$0.018 loss per share (down from AU$0.002 loss in FY 2021). Revenue: AU$19.3m (up 131% from FY 2021). Net loss: AU$4.45m (loss widened AU$4.07m from FY 2021). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Ankündigung • Jul 29
Beamtree Holdings Limited to Report Fiscal Year 2022 Results on Aug 24, 2022 Beamtree Holdings Limited announced that they will report fiscal year 2022 results on Aug 24, 2022 Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Chairman Mike Hill is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 16
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: AU$0.008 loss per share (down from AU$0.001 profit in 1H 2021). Revenue: AU$7.13m (up 91% from 1H 2021). Net loss: AU$1.86m (down AU$1.96m from profit in 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 82%, compared to a 73% growth forecast for the industry in Australia. Recent Insider Transactions • Sep 23
Non-Executive Director recently bought AU$52k worth of stock On the 21st of September, Stephen Borness bought around 100k shares on-market at roughly AU$0.52 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold AU$5.1m more in shares than they bought in the last 12 months. Recent Insider Transactions • Sep 11
Executive recently sold AU$5.2m worth of stock On the 9th of September, Paul O'Connor sold around 9m shares on-market at roughly AU$0.58 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$5.2m more than they bought in the last 12 months. Ankündigung • Aug 31
Beamtree Holdings Limited (ASX:BMT) entered into a binding agreement to acquire Potential X Ltd from Health Roundtable Limited, Duance Attree and others for AUD 18.7 million. Beamtree Holdings Limited (ASX:BMT) entered into a binding agreement to acquire Potential X Ltd from Health Roundtable Limited, Duance Attree and others for AUD 18.7 million on August 30, 2021. consideration to Potential(x) shareholders comprising up to 30 million shares in Beamtree and AUD 4 million cash consideration. The share consideration to be issued on completion of the acquisition comprises 12.7 million ordinary shares and 6 million performance shares. The performance shares will convert (1:1) into ordinary shares on satisfaction of a vesting condition based on the achievement of revenue targets for FY22. The issue of the remaining 11.3 million shares will be deferred for 24 months as security against any warranty and indemnity claims. This implies an enterprise value for Potential(x) of $19.6m on a debt free, cash free basis. The acquisition is fully funded. Potential(x)’s Managing Director and majority shareholder, Duane Attree, will join Beamtree’s executive team and become a substantial shareholder. Potential(x) shareholders will own 9.6% of Beamtree. Management and the Board of Beamtree will own 34% of the company. The transaction is also subject to certain customary conditions precedent for a transaction of this nature, including no material adverse change in respect of Potential(x). Completion is expected to occur by the end of September 2021. Reported Earnings • Aug 29
Full year 2021 earnings released: AU$0.002 loss per share (vs AU$0.003 profit in FY 2020) The company reported a decent full year result with improved revenues, although earnings and control over costs were weaker. Full year 2021 results: Revenue: AU$8.94m (up 116% from FY 2020). Net loss: AU$383.6k (down 200% from profit in FY 2020). Ankündigung • Aug 27
Beamtree Holdings Limited (ASX:BMT) acquired Ainsoff Pty Ltd for AUD 1 million. Beamtree Holdings Limited (ASX:BMT) acquired Ainsoff Pty Ltd for AUD 1 million on August 27, 2021. Under the terms, the consideration will be paid in combination of cash and common stock. Post completion, founders of Ainsoff Pty Ltd will join Beamtree, as well as three ready-for-market product applications will also be acquired. As of August 27, 2021, the securities of Beamtree Holdings Limited will be placed in trading halt at the request of BMT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 31 August 2021 or when the announcement is released to the market.
Beamtree Holdings Limited (ASX:BMT) completed the acquisition of Ainsoff Pty Ltd on August 27, 2021. Recent Insider Transactions Derivative • Jul 02
Independent Non-Executive Director exercised options to buy AU$300k worth of stock. On the 25th of June, Andrew James Gray exercised options to buy 750k shares at a strike price of around AU$0.20, costing a total of AU$150k. This transaction amounted to 12% of their direct individual holding at the time of the trade. Since September 2020, Andrew James' direct individual holding has increased from 1.35m shares to 7.10m. Company insiders have collectively bought AU$213k more than they sold, via options and on-market transactions, in the last 12 months. Executive Departure • Apr 19
Company Secretary has left the company On the 13th of April, Maggie Niewidok's tenure as Company Secretary ended after 1.8 years in the role. We don't have any record of a personal shareholding under Maggie's name. A total of 2 executives have left over the last 12 months. Ankündigung • Mar 19
PKS Holdings Limited Announces the Appointment of Jim Birch Am as a Non-Executive Director The Board of PKS Holdings Limited announced the appointment of Australian healthcare leader Jim Birch AM as a Non-Executive Director. Jim Birch has more than 30 years' experience in implementing technological change in the healthcare industry, having previously served as Chair of the Australian Digital Health Agency, Deputy Chair of the Independent Hospital Pricing Authority, CEO of the SA Department of Health, and global healthcare leader
for consulting firm EY. He is currently Chair of the Little Company of Mary Health Care (Calvary), the Australian Red Cross Blood Service (now known as Lifeblood), the SA Women's and Children's Health Network and Clevertar Pty Ltd. PKS Chair, Mike Hill, is thrilled to have Jim joining the board as the business looks to expand its offering into hospitals and health services across the country and internationally. Ankündigung • Mar 03
PKS Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.22 million. PKS Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.22 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,342,857
Price\Range: AUD 0.35
Transaction Features: Subsequent Direct Listing Reported Earnings • Feb 24
First half 2021 earnings released: EPS AU$0.001 (vs AU$0.002 in 1H 2020) The company reported a mediocre first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: AU$3.73m (up 97% from 1H 2020). Net income: AU$96.3k (down 53% from 1H 2020). Profit margin: 2.6% (down from 11% in 1H 2020). Ankündigung • Jan 29
PKS Holdings Limited Executes AUD 2.34 million Renewal Agreement with Philips PKS Holdings Limited announced it has renewed and amended its ongoing Software License and Maintenance Agreement with Philips Nederland B.V. ("Philips") for the PKS RippleDown CDS Software. The Agreement extension is forecasted to be in excess of €1.5 million (AUD 2.34 million) and has been signed with a backdated effective date of 1 September 2020. The Renewal Agreement will see Philips offer the PKS' RippleDown product as an integral part of their newly developed clinical software platform. The term is extended to 30 August 2025 and includes automatic 1-year renewal periods. Is New 90 Day High Low • Dec 31
New 90-day high: AU$0.38 The company is up 46% from its price of AU$0.26 on 02 October 2020. The Australian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$0.42 per share. Ankündigung • Nov 19
PKS Holdings Limited Signs USD 1.65 Million Agreement for National Health Data Audit The Board of PKS Holdings Limited announced that PKS has entered into a new material contract to provide health data audit services to more than 270 hospitals in the Middle East. This underpins the international expansion strategy to provide further health data audit services as a precursor towards the provision of its wholly owned SaaS-based products including PICQ® and RISQTM. PKS signed its largest ever single agreement for a USD 1.65 million (~AUD 2.25 million) strategic consultancy engagement to audit health data in public hospitals in the Kingdom of Saudi Arabia. PKS' core software products PICQ® and RISQTM will be integral in the delivery of the health data audit consulting services. Is New 90 Day High Low • Nov 19
New 90-day high: AU$0.36 The company is up 38% from its price of AU$0.26 on 21 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$0.35 per share. Is New 90 Day High Low • Oct 09
New 90-day high: AU$0.33 The company is up 91% from its price of AU$0.17 on 10 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$0.35 per share. Ankündigung • Oct 06
PKS Holdings Limited Appoints Tim Kelsey as New CEO The Board of PKS Holdings Limited announced the appointment of data analytics and digital transformation expert, Tim Kelsey as the new Chief Executive Officer (CEO) to lead the next phase of growth. The Company's current Managing Director, Ron van der Pluijm will support Tim throughout the transition and continue in his role as non-executive Director. Tim Kelsey is an internationally regarded leader in data analytics and digital transformation. He is currently senior vice-president of Analytics International for HIMSS. Tim's start date is to be confirmed but will be prior to the end of calendar 2020.